Retatrutide, a experimental dual activator of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) binding site , is exhibiting promising results in early patient studies. Current research https://bookmarksea.com/story21324439/retatrutide-emerging-studies-and-potential-therapeutic-uses